United Therapeutics (NASDAQ:UTHR) CEO Sells $5,320,665.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction that occurred on Wednesday, October 21st. The stock was sold at an average price of $560.07, for a total transaction of $5,320,665.00. Following the sale, the chief executive officer owned 324,443 shares of the company’s stock, valued at approximately $181,710,791.01. The trade was a 2.84% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

United Therapeutics Stock Up 3.8%

UTHR traded up $21.30 during trading hours on Thursday, hitting $584.79. The stock had a trading volume of 878,421 shares, compared to its average volume of 556,722. United Therapeutics Corporation has a 1 year low of $409.07 and a 1 year high of $609.35. The company’s fifty day simple moving average is $515.71 and its 200 day simple moving average is $539.59. The stock has a market cap of $25.08 billion, a PE ratio of 20.92, a price-to-earnings-growth ratio of 3.96 and a beta of 0.49.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%. The business had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. During the same quarter in the previous year, the firm earned $6.41 EPS. The company’s quarterly revenue was down 1.9% compared to the same quarter last year. As a group, equities analysts expect that United Therapeutics Corporation will post 26.40 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. BlackRock Inc. bought a new position in United Therapeutics during the 2nd quarter valued at approximately $2,868,735,000. Jupiter Topco LLC bought a new stake in United Therapeutics in the second quarter worth $450,140,000. Bank of New York Mellon Corp purchased a new stake in shares of United Therapeutics in the second quarter worth $159,522,000. Caisse de depot et placement du Quebec purchased a new stake in shares of United Therapeutics in the second quarter worth $154,304,000. Finally, Legal & General Group Plc purchased a new stake in shares of United Therapeutics in the second quarter worth $112,209,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on UTHR shares. Jefferies Financial Group reaffirmed a “buy” rating and issued a $728.00 price objective on shares of United Therapeutics in a research note on Wednesday, October 14th. Morgan Stanley boosted their price target on shares of United Therapeutics from $515.00 to $566.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 7th. UBS Group set a $725.00 price target on shares of United Therapeutics in a research note on Monday. Cantor Fitzgerald restated an “overweight” rating on shares of United Therapeutics in a research report on Thursday, October 1st. Finally, The Goldman Sachs Group restated a “sell” rating and issued a $368.00 target price on shares of United Therapeutics in a report on Thursday, October 15th. Twelve analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, United Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $650.43.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for patients with life-threatening conditions, particularly pulmonary arterial hypertension (PAH). The company’s portfolio includes Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable treprostinil product; and Orenitram, an oral treprostinil therapy. These treatments are designed to improve exercise ability and delay disease progression in people with PAH.

The company also markets Unituxin, an antibody therapy used as part of treatment for high-risk neuroblastoma, a type of childhood cancer.